Contrafect (CFRX)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company is also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator-associated pneumonia, bloodstream infections, complicated urinary tract infections, and surgery-related infections. Additionally, it is developing CF-296, an osteomyelitis and PJI treatment, which is in preclinical trials for the treatment of joint infections. In addition, the company is developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, it develops CF-296, an engineered lysin, used for the treatment of invasive infections caused by staphylococcus aureus, including biofilm-related infections in prosthetic joints and indwelling devices, as well as osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.